Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Double-Blind, Placebo Controlled, Dose-Escalation Safety, Pharmacokinetic and Pharmacodynamic Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers

NCT03077477 is registered in ClinicalTrials.gov with Aminex Therapeutics, Inc. as lead sponsor.

NCT NCT03077477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03077477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Double-Blind, Placebo Controlled, Dose-Escalation Safety, Pharmacokinetic and Pharmacodynamic Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers
Lead sponsor
Aminex Therapeutics, Inc.
Phase
Phase 1
Overall status
Withdrawn
Start date
June 12, 2018
Completion date
June 12, 2018
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

medication toxicity, neoplasms, tolerance